Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-08-29
2006-08-29
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S186100, C530S300000
Reexamination Certificate
active
07097843
ABSTRACT:
The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.
REFERENCES:
patent: 4741872 (1988-05-01), DeLuca et al.
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 5075109 (1991-12-01), Tice et al.
patent: 5413797 (1995-05-01), Khan et al.
patent: 5547846 (1996-08-01), Bartsch et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5643605 (1997-07-01), Cleland et al.
patent: 5648459 (1997-07-01), Cole et al.
patent: 5656297 (1997-08-01), Bernstein et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5695770 (1997-12-01), Raychaudhuri et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5705151 (1998-01-01), Dow et al.
patent: 5709860 (1998-01-01), Raychaudhuri et al.
patent: 5733548 (1998-03-01), Restifo et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5846540 (1998-12-01), Restifo et al.
patent: 6007806 (1999-12-01), Lathe et al.
patent: 6013258 (2000-01-01), Urban et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6183746 (2001-02-01), Urban et al.
patent: 6582704 (2003-06-01), Urban et al.
patent: 60-147368 (1985-07-01), None
patent: WO 92/10513 (1992-06-01), None
patent: WO 93/22338 (1993-11-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/04171 (1994-03-01), None
patent: WO 94/04557 (1994-03-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 94/21680 (1994-09-01), None
patent: WO 94/23738 (1994-10-01), None
patent: WO 95/24929 (1995-11-01), None
patent: WO 96/00583 (1996-01-01), None
patent: WO 97/17063 (1997-05-01), None
patent: WO 97/33602 (1997-09-01), None
patent: WO 97/34617 (1997-09-01), None
patent: WO 97/34621 (1997-09-01), None
patent: WO 97/42940 (1997-11-01), None
patent: WO 98/31398 (1998-07-01), None
patent: WO 99/45954 (1999-09-01), None
Choo et al , Journal of Virology, Feb. 1989, vol. 63, No. 2, pp. 782-789.
Collins et al., “processing of Exogenous Lipsome-Encapsulat4ed Antigens In Vivo Generates Class I MHC-restricted T Cell Responses,” The Journal of Immunology, 148:3336-3341, No. 11, Jun. 1, 1992.
Elliot et al., “Processing of Major Histocompatibility Class I-restricted Antigens in the Endoplasmic Reticulum,” The Journal of Experimental Medicine, 181:1481-1491, Apr. 1995.
Donnelly et al., “immunization with DNA,” Journal of Immunological Methods, 176:145-152, No. 2, 1994.
Feltkamp et al., “Vaccination with cytotoxic T Lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells,” European Journal of Immunology, 23:2242-2249, 1993.
Fries et al., “Liposomal Malaria Vaccine in Humans: A Safe and Potent adjuvant Strategy,” Proceedings of the National Academy of Sciences, 89:358-362, Jan. 1992.
Fynan et al., “DNA Vaccines: Protective Immunizations by Parenteral, Mucosal, and Gene-Gun Inoculations,” Proceedings of the National Academy of Sciences, 90:11478-11482, 1993.
Gao et al., “Tumor-Associated E6 Protein of Human Papillomavirus Type 16 Contains an Unusual H-2kb-Restricted Cytotoxic T Cell Epitope,” The Journal of Immunology, 155:5519-5526, 1995.
Hurtenbach et al., “Prevention of Autoimmune Diabetes in Non-Obese Diabetic Mice by Treatment with a Class II Major Histocompatability Complex-blocking Peptide,” The Journal of Experimental Medicine, 177:1499-1504, 1993.
Jochmus et al., “Specificity of human cytotoxic T Lymphocytes induced by a human papillomavirus type 16 E7-derived peptide,” The Journal of General Virology, 78:1689-1695, 1997.
Kadish et al., “Cell-mediated immune reponses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific,” The Journal of General Viology, 75:2277-2284, 1994.
Kadish et al., “Lymphoproliferative Responses to Human Papillomavirus (HPV) Type 16 Proteins E6 and E7: Outcome of HPV Infection and Associated Neoplasia,” Journal of the National Cancer Institute, 89:1285, 1997.
Kast et al., “Human Leukocyte Antien-A2.1 Restricted Candidate Cytotoxic T Lymphocyte Epitopes of Human Papillomavirus Type 16 E6 and E7 Proteins Identified by Using the Processing-Defective Human Cell Line T2,” The Journal of Immunotherapy, 14:115-120, 1993.
Kast et al., “Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins,” The Journal of Immunology, 152:3904-3912, 1994.
Lin et al., “Treatment of Established Tumors with a Novel Vaccine that Enhances Major Histocompatibility Class II Presentation of Tumor Antigen,” Cancer Research, 56:21-26, 1996.
Loftus et al., “Analysis of MHC-specific peptide motifs: applications in immunotherapy,” Advances in Experimental Medicine and Biology; Immunobiology of proteins and peptides VIII. Manipulation or modulation of the immune response, 1995, pp. 201-210.
Madden et al., “The Antigenic Identity of Peptide-MHC Complexes: A Comparison of the conformations of Five Viral Peptides Presented by HLA-A2,” CELL, 75:693-708, Nov. 19, 1993.
Mowat et al., “ISCOMS—A Novel Strategy for Mucosal Immunization?”, Immunology Today, 12:383-385, 1991.
Nabel et al., “Transduction of a Foreign Histocompatability Gene into the Arterial Wall Induces Vasculitis,” Proceedings of the National Academy of Sciences, 89:5157-5161, No. 11, Jun. 1992.
Osband et al., “Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy,” Immunology Today, 11:193-195, 1990.
Reddy et al., “In Vivo Cytotoxic T Lymphocyte Induction with Soluble Proteins Administered in Liposomes,” The Journal of Immunology, 148:1585-1589, No. 5, Mar. 1992.
Ressing et al., “Occasional Memory Cytotoxic T-Cell Responses of Patients with Human Papillomavirus Type 16-positive Cervical Lesions against a Human Leukocyte Antigen-A 0201-restricted E7-encoded Epitope,” Cancer Research, 56:582-588, Feb. 1, 1996.
Ressing et al., “human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A 0201 Binding Peptides,” The Journal of Immunology, 154:5934-5943, Jun. 1, 1995.
Shrine et al., “Pangaea Aims Naturally Processed Peptides at First viral Target: Human Papilloma Virus,” Bioworld Today, The Biotechnology Newspaper, 7:1-2, May 15, 1996.
Stellar et al., “Human Papillomavirus Immunology and Vaccine Prospects,” Journal of the National Cancer Institute Monographs, No. 21, 1996, pp. 145-148.
Takahashi et al., “Induction of CD8 Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs,” NATURE, 344:873-875, Apr. 1990.
Tarpey et al., “Human Cytotoxic T Lymphocytes Stimulated by Endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif,” IMMUNOLOGY, 81:222-227, 1994.
Tsukui et al., “Interleukin 2 Production in vitro by Peripheral Lymphocytes in response to Human Papillomavirus-derived peptides: Correlation with Cervical Pathology,” Cancer Research, 56:3855-4085, 1996.
Urban et al., “A subset of HLA-B27 Molecules contains peptides much longer than nonamers,” Proceedings of the National Academy of Sciences, 91:1534-1538, Feb. 1994.
Vitiello et al., Development of a Lipopeptide Based Therapeutic Vaccine to Treat chronic HBV Infection, The Journal O Fclinical Investigation, 95:341-349, Jan. 1995.
Vitiello et al., “Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex,” J.
Chicz Roman M.
Collins Edward J.
Hedley Mary Lynne
Urban Robert G.
Fish & Richardson P.C.
MGI Pharma Biologics, Inc.
Salimi Ali R.
LandOfFree
Immunogenic peptides from the HPV E7 protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic peptides from the HPV E7 protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic peptides from the HPV E7 protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3650422